Skip directly to site content

Panel:   Cefiderocol Verification (FDC) (Custom)
AR Bank # 0033 Acinetobacter baumannii
Study ID: CarbaNP-02

Biosample Accession #: SAMN04014874

MLST: ST85(Pasteur), ST1089(Oxford)

This panels contains isolates from other AR Bank collections/panels.

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Gram Negative Carbapenemase Detection (CarbaNP)  |  ARLN Verification (Custom)  |  Cefiderocol Verification (FDC) (Custom)  |  GN7F ARLN (Custom)  |  GAIHN (Custom)

MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 2S
Ampicillin/sulbactam 1>32R
Cefepime >32R
Cefepime/zidebactam 5>64---
Cefiderocol 16R
Cefotaxime >64R
Ceftazidime >128R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 41I
Doripenem >8R
Gentamicin 16R
Imipenem 64R
Imipenem+chelators 34---
Levofloxacin 8R
Meropenem >8R
Piperacillin/tazobactam 1>128R
Tetracycline <=2S
Tigecycline 2<=0.5---
Tobramycin 16R
Trimethoprim/sulfamethoxazole 1>8R
S – I –R Interpretation (INT) derived from CLSI 2022 M100 S32

1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
5 Cefepime to zidebactam ratio (1:1)
Molecular Mechanisms of Resistance
Aminoglycoside ant(3")-IIa
Beta-lactam NDM-1, OXA-94
Bleomycin ble-MBL
Efflux pumps/Other ABAF
Sulfonamides sul2
The resistance mechanisms listed were identified by analysis of whole genome sequence using the ResFinder database (last updated June 2, 2016 and accessed on October 25, 2016). This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of the ResFinder database or other antimicrobial resistance gene databases. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired.
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

Temperature: 35°C
Atmosphere: Aerobic


Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.

Storage Temperature & Biosafety

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
03/09/23Gene was added: ABAF
03/09/23Category was added: Efflux pumps/Other
03/09/23Gene was added: ble-MBL
03/09/23Gene was added: ant(3")-IIa
03/09/23Category was added: Bleomycin
03/09/23Category was added: Aminoglycoside
12/19/22MLST was updated: from --- to ST1089(Oxford)
12/19/22MLST was updated: from --- to ST85(Pasteur)
12/07/22MIC was updated with a new value for Cefepime/zidebactam: from --- to >64
12/07/22Drug was added: Cefepime/zidebactam
Top of Page